pharma · Diabetes Mellitus · Hemophilia A
Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179
Phase 1 · small molecule · Glioblastoma
Ixazomib citrate (NINLARO) is an oral proteasome inhibitor developed by Takeda Pharmaceutical Company for the treatment of glioblastoma. The program represents an investigational application of an already-approved oncology agent to a new indication. Ixazomib is a small-molecule proteasome inhibitor approved in the Unit
Internal code IRB00083003
Ixazomib citrate (NINLARO) is an oral proteasome inhibitor developed by Takeda Pharmaceutical Company for the treatment of glioblastoma. The program represents an investigational application of an already-approved oncology agent to a new indication. Ixazomib is a small-molecule proteasome inhibitor approved in the United States (NDA208462) and Japan (March 2017) for multiple myeloma. The glioblastoma program entered Phase 1 clinical evaluation under IRB protocol IRB00083003, with the most recent milestone recorded on March 26, 2021. The trial, identified as NCT02630030, has completed enrollment and data collection. Takeda's strategy appears focused on exploring proteasome inhibition as a potential therapeutic approach in this difficult-to-treat central nervous system malignancy. Current development status indicates the program has concluded Phase 1 activities, though advancement to subsequent phases and regulatory pathway decisions remain undisclosed. The competitive landscape for glioblastoma treatment includes established standards of care such as the Stupp protocol (external beam radiation therapy and temozolomide), surgical resection, and emerging investigational agents in Phase 3 development including temozolomide combinations, cediranib, and various other small-molecule and immunotherapy approaches.
Glioblastoma remains one of the most aggressive and treatment-resistant human malignancies, with median overall survival of approximately 14–15 months despite multimodal therapy. The disease represents a significant unmet medical need, as standard-of-care approaches (Stupp protocol with radiation and temozolomide) have shown limited efficacy gains over the past two decades. Proteasome inhibition represents a mechanistically distinct approach to glioblastoma treatment, potentially addressing chemotherapy resistance and tumor microenvironment factors that limit conventional therapies. The commercial significance of glioblastoma therapeutics is substantial; any agent demonstrating meaningful survival or progression-free survival benefit could command premium pricing given the limited treatment options and high mortality burden. Ixazomib's oral bioavailability and established safety profile in multiple myeloma patients provide a potential advantage over intravenous or more toxic alternatives. However, the Phase 1 completion without disclosed Phase 2 advancement suggests either negative tolerability signals in the CNS setting, insufficient efficacy signals, or strategic deprioritization by Takeda. The competitive landscape includes multiple Phase 3 programs (temozolomide variants, cediranib, enzastaurin, edotecarin, and combination approaches), indicating active investment in glioblastoma drug development. Success in this indication would establish proteasome inhibition as a viable CNS-penetrant strategy and could support label expansion or combination therapy approaches.
Drug Class: Proteasome inhibitor (small-molecule oncology agent)
Modality: Small molecule
Route of Administration: Oral
Molecular Target: Not disclosed in available facts
Mechanism of Action: Not disclosed in available facts; presumed proteasome inhibition based on established mechanism in multiple myeloma indication
Related Therapies: Ixazomib is structurally and mechanistically related to other proteasome inhibitors (bortezomib, carfilzomib) approved for hematologic malignancies. In the glioblastoma space, it competes with DNA-damaging agents (temozolomide, lomustine, edotecarin), targeted kinase inhibitors (cediranib, enzastaurin), and combination immunotherapy approaches.
First Approval: Ixazomib citrate (NINLARO) approved in Japan (March 2017) and United States (NDA208462) for multiple myeloma; glioblastoma indication remains investigational
Patent Status: Not disclosed in available facts
Also known as: GBM, GBM (glioblastoma), WHO grade IV glioma, glioblastoma (disease), glioblastoma multiforme, glioblastoma multiforme (disease)
Prevalence: Point prevalence: 1-9 / 100 000 (Worldwide) — source: Orphanet, validated.
The most malignant astrocytic tumor (WHO grade IV). It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma, IDH-mutant), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma, IDH- wildtype). (Adapted from WHO)
ClinicalTrials.gov lists 877 registered studies for Glioblastoma (AACT aggregate).
Phase breakdown: NA (252), PHASE2 (223), PHASE1 (206), PHASE1/PHASE2 (86), EARLY_PHASE1 (49), PHASE3 (45), PHASE2/PHASE3 (11), PHASE4 (5)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0018177), Orphanet — glioblastoma, NCT00001148, NCT00001171, NCT00009035, NCT00028158, NCT00029783, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
NINLARO approved in Japan for multiple myeloma
Ixazomib citrate approved by PMDA for multiple myeloma indication.
NINLARO approved in United States for multiple myeloma
Ixazomib citrate approved by FDA under NDA208462 for multiple myeloma indication; specific approval date not disclosed in facts.
Phase 1 glioblastoma trial initiated
Ixazomib Phase 1 evaluation in glioblastoma initiated under IRB protocol IRB00083003 (NCT02630030).
Phase 1 glioblastoma trial completed
Phase 1 clinical trial in glioblastoma completed; specific results and advancement decisions not disclosed.
The glioblastoma therapeutic landscape includes established standard-of-care approaches and multiple investigational programs at advanced stages. Surgical tumor resection combined with the Stupp protocol (external beam radiation therapy and temozolomide) and emerging modalities such as GammaTile radiation therapy implantation represent the current clinical standard, sponsored by GT Biopharma and others. Temozolomide, a DNA-alkylating agent, remains the backbone of glioblastoma therapy and is being evaluated in multiple Phase 3 combinations (Adaptive Biotechnologies Corp, Novo Nordisk A/S with Keytruda). Phase 3 programs include cediranib (AstraZeneca, a VEGFR inhibitor), enzastaurin (Eli Lilly, a protein kinase C inhibitor), edotecarin (Pfizer, a topoisomerase I inhibitor), and combination approaches with lomustine (Lacuna Pharma Pty Ltd). Adaptive Biotechnologies Corp is advancing a multi-agent Phase 3 program combining ADI-PEG-20, troriluzole, and AZD1390. Ixazomib's proteasome inhibition mechanism represents a distinct approach but enters a crowded field with multiple Phase 3 competitors and limited disclosed efficacy data from the Phase 1 glioblastoma trial. The completion of Phase 1 without apparent advancement to Phase 2 suggests potential challenges in CNS penetration, tolerability, or efficacy signals compared to competing approaches.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| Stereotactic Radiation Therapy | GT Biopharma | other | approved |
| IRON OXIDE (E172) | Disc Medicine | small_molecule | approved |
| Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide) | GT Biopharma | other | approved |
| Temozolomide | Adaptive Biotechnologies Corp | small_molecule | phase_3 |
| enzastaurin | Eli Lilly and Company | small_molecule | phase_3 |
| Edotecarin | Pfizer | small_molecule | phase_3 |
| LOMUSTINE, 4-L-[131I]iodo-phenylalanine, LOMUSTINE | Lacuna Pharma Pty Ltd | small_molecule | phase_3 |
| ADI-PEG-20, Troriluzole, AZD1390 | Adaptive Biotechnologies Corp | small_molecule | phase_3 |
| TEMOZOLOMIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, saline solution for infusion | Novo Nordisk A/S | small_molecule | phase_3 |
| Temodal 100 mg hard capsules, Temodal 250 mg hard capsules, Placebo, 2-Hydroxyoleic acid sodium salt, Temodal 140 mg hard capsules, Temodal 5 mg hard capsules, Temodal 20 mg hard capsules, Temodal 180 mg hard capsules | Lacuna Pharma Pty Ltd | small_molecule | phase_3 |
| Cediranib | AstraZeneca | small_molecule | phase_3 |
| LOMUSTINE | Ningbo Cancer Hospital | small_molecule | phase_3 |
| CARMUSTINE | — | Glutathione reductase inhibitor | Approved |
| BEVACIZUMAB | — | Vascular endothelial growth factor A inhibitor | Approved |
| TRABEDERSEN | — | Transforming growth factor beta-2 mRNA antisense inhibitor | Phase 3 |
| TOFACITINIB | — | Janus Kinase (JAK) inhibitor | Phase 3 |
| RINDOPEPIMUT | — | Epidermal growth factor receptor erbB1 vaccine antigen | Phase 3 |
| OMBIPEPIMUT-S | — | Wilms tumor protein vaccine antigen | Phase 3 |
| NIVOLUMAB | — | Programmed cell death protein 1 inhibitor | Phase 3 |
| NIMOTUZUMAB | — | Epidermal growth factor receptor erbB1 inhibitor | Phase 3 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States (FDA): Ixazomib citrate (NINLARO) approved under NDA208462 for multiple myeloma; glioblastoma indication remains investigational with no FDA submission or approval disclosed.
Japan (PMDA): Ixazomib citrate (NINLARO) approved March 2017 for multiple myeloma; glioblastoma indication not approved.
European Union (EMA): Regulatory status for ixazomib in any indication not disclosed in available facts.
China (NMPA): Regulatory status not disclosed in available facts.
Glioblastoma Program Status: Phase 1 trial (NCT02630030) completed March 26, 2021. No IND, CTA, or regulatory filing for glioblastoma indication disclosed. No Phase 2 initiation or advancement decision disclosed. Regulatory pathway and future development intentions not yet disclosed.
Ixazomib citrate (NINLARO) is an oral proteasome inhibitor approved for multiple myeloma in the United States and Japan. The compound is being investigated in a Phase 1 trial for glioblastoma, an aggressive brain cancer, though this indication remains investigational.
No. Ixazomib is approved only for multiple myeloma in the US and Japan. The glioblastoma program completed Phase 1 evaluation in March 2021, but no Phase 2 advancement or regulatory approval for glioblastoma has been disclosed.
Ixazomib is a proteasome inhibitor, a class of drugs that blocks the proteasome—a cellular structure responsible for degrading proteins. In multiple myeloma, proteasome inhibition triggers cancer cell death. The mechanism in glioblastoma is presumed similar but remains investigational.
Takeda Pharmaceutical Company developed and manufactures ixazomib citrate under the brand name NINLARO. Takeda is also the sponsor of the glioblastoma Phase 1 trial.
Ixazomib is administered orally (by mouth) as a capsule, which is a significant advantage over intravenous proteasome inhibitors like bortezomib.
NCT02630030 is the Phase 1 trial evaluating ixazomib in glioblastoma. The trial was conducted under IRB protocol IRB00083003 and completed on March 26, 2021.
Specific results from NCT02630030 have not been disclosed in available facts. The trial completed in March 2021, but efficacy, safety, and pharmacokinetic data have not been published or reported.
No Phase 2 advancement has been disclosed. The Phase 1 trial completed in March 2021, but Takeda has not announced a Phase 2 initiation or provided a development update.
The specific mechanism of action in glioblastoma has not been disclosed. Ixazomib's proteasome inhibition mechanism is established in multiple myeloma, but its activity in glioblastoma remains investigational.
The specific molecular target of ixazomib has not been disclosed in available facts. As a proteasome inhibitor, it is presumed to target the 20S proteasome complex.
Ixazomib citrate (NINLARO) was approved in Japan by the PMDA in March 2017 for multiple myeloma. FDA approval in the United States occurred under NDA208462, though the specific date is not disclosed in available facts.
Competitors include established therapies (temozolomide, radiation therapy, surgical resection) and investigational Phase 3 programs: cediranib (AstraZeneca), enzastaurin (Eli Lilly), edotecarin (Pfizer), and temozolomide combinations with immunotherapy or other agents.
Glioblastoma has a median overall survival of approximately 14–15 months despite multimodal therapy with the Stupp protocol. New treatment approaches with improved efficacy and tolerability are urgently needed.
Proteasome inhibitors trigger cancer cell death through multiple mechanisms and have shown activity in hematologic malignancies. Exploration in glioblastoma represents a mechanistically distinct approach to address chemotherapy resistance and tumor microenvironment factors.
The Phase 1 trial (NCT02630030) completed on March 26, 2021. No further development milestones, Phase 2 initiation, or regulatory filings have been disclosed.
No partner or licensing arrangement has been disclosed for the ixazomib glioblastoma program. Takeda is the sole sponsor.
Projected peak sales figures for ixazomib in glioblastoma have not been disclosed in available facts.
Ixazomib → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Takeda's Phase 1 evaluation of ixazomib in glioblastoma represents a reasonable investigational strategy to explore proteasome inhibition in CNS malignancy, leveraging the established safety and manufacturing infrastructure of NINLARO. However, the absence of disclosed Phase 2 advancement or publication of Phase 1 data (as of the latest milestone March 2021) suggests either negative signals or strategic deprioritization. The lack of transparency regarding trial results is notable and may indicate disappointing efficacy, tolerability concerns related to CNS penetration, or internal portfolio prioritization decisions.
Competitive Implications: Multiple Phase 3 programs in glioblastoma (cediranib, temozolomide combinations, enzastaurin, edotecarin) are advancing in parallel, creating a crowded competitive environment. Ixazomib's oral route and established safety profile are advantages, but the Phase 1 completion without apparent advancement suggests it may not offer sufficient differentiation or efficacy benefit to justify further investment relative to competing approaches. The proteasome inhibition mechanism remains underexplored in CNS malignancies and may face inherent challenges in CNS penetration or tumor microenvironment engagement.
Future Catalysts: Publication of Phase 1 data would clarify tolerability, pharmacokinetics, and any preliminary efficacy signals. A Phase 2 initiation decision (or formal discontinuation announcement) would indicate Takeda's commitment to the program. Regulatory guidance on proteasome inhibitor development in glioblastoma could influence strategy.
Expected Milestones: No specific milestones disclosed. Potential future catalysts include Phase 1 data publication, Phase 2 initiation or discontinuation announcement, and regulatory interactions with FDA regarding CNS-penetrant proteasome inhibitor development.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.